Artificial Intelligence

AI drug trial hits Phase III for IPF, rentosertib shows promise

Insilico Medicine’s AI‑discovered drug rentosertib advances to Phase III for idiopathic pulmonary fibrosis, showing a 98.4 mL FVC gain in a 71‑patient trial.